Monitor upcoming clinical data readouts for OCU400 (Q1 2027) and OCU410 (March 2026), which could be catalysts. The extended cash runway into Q4 2026 reduces near-term dilution risk, but investors should watch for potential warrant exercises from the Janus Henderson financing that could extend funding into Q2 2027.
OCGN drugs
OCGN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $1.96entry
- T+1 · 9mo ago −11.22%α −10.65% · $1.74
- T+5 · 8mo ago +17.35%α +18.68% · $2.30
- T+20 · 8mo ago −8.67%α −4.26% · $1.79
- T+60 · 6mo ago −28.06%α −38.15% · $1.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net losses, but highlighted significant clinical progress including completed enrollment in its OCU400 Phase 3 trial and positive preliminary data for OCU410. The company secured $22.5 million in financing to extend its cash runway into Q4 2026.
Key Financial Metrics
Key Facts
- Completed enrollment in OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa; topline data expected Q1 2027
- Positive preliminary Phase 2 data for OCU410 in geographic atrophy showed 46% lesion growth reduction
- Secured $22.5 million in gross proceeds through a registered direct offering in January 2026
- Cash and restricted cash totaled $18.9 million as of December 31, 2025, down from $58.8 million a year earlier
- Reported net loss of $0.06 per share in Q4 2025, compared to $0.05 per share in Q4 2024
Financial Impact
Net loss increased to $17.7 million in Q4 2025 from $13.9 million in Q4 2024, with cash declining by $39.9 million year-over-year
Risk Factors
- Cash position decreased significantly from $58.8 million to $18.9 million year-over-year, despite recent financing
- Net losses increased year-over-year, with R&D expenses rising from $32.1 million in 2024 to $39.8 million in 2025
- Future funding remains dependent on warrant exercises and potential partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-023288 |
| Document: tm267731d1_ex99-2.htm | 0001104659-26-023288 |
| Document: tm267731d1_8k.htm | 0001104659-26-023288 |
| Document: 0001104659-26-023288-index-headers.html | 0001104659-26-023288 |
| Document: 0001104659-26-023288-index.html | 0001104659-26-023288 |
| Document: 0001104659-26-023288.txt | 0001104659-26-023288 |
Track record
23 reports on OCGN
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
- Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
- Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers